Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC). Two anti-programmed death-1 (PD-1) monoclonal antibodies (pembrolizumab and nivolumab) and three anti-PD ligand-1 (PD-L1) monoclon...

Full description

Bibliographic Details
Main Authors: Jhe-Cyuan Guo, Yu-Chieh Tsai, Yeong-Shiau Pu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Urological Science
Subjects:
Immune checkpoint
programmed death ligand-1
programmed death-1
urothelial carcinoma
Online Access:http://www.e-urol-sci.com/article.asp?issn=1879-5226;year=2019;volume=30;issue=1;spage=2;epage=7;aulast=Guo

Internet

http://www.e-urol-sci.com/article.asp?issn=1879-5226;year=2019;volume=30;issue=1;spage=2;epage=7;aulast=Guo

Similar Items